Top-Rated StocksTop-RatedNASDAQ:QURE uniQure (QURE) Stock Price, News & Analysis $15.75 -0.04 (-0.25%) Closing price 04:00 PM EasternExtended Trading$15.76 +0.02 (+0.10%) As of 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About uniQure Stock (NASDAQ:QURE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get uniQure alerts:Sign Up Key Stats Today's Range$15.48▼$15.8750-Day Range$13.28▼$16.1852-Week Range$4.45▼$19.18Volume617,456 shsAverage Volume964,865 shsMarket Capitalization$864.20 millionP/E RatioN/ADividend YieldN/APrice Target$37.45Consensus RatingBuy Company Overview uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands. Read More uniQure Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreQURE MarketRank™: uniQure scored higher than 48% of companies evaluated by MarketBeat, and ranked 602nd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatinguniQure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageuniQure has only been the subject of 3 research reports in the past 90 days.Read more about uniQure's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for uniQure are expected to grow in the coming year, from ($3.75) to ($3.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of uniQure is -4.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of uniQure is -4.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about uniQure's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.99% of the float of uniQure has been sold short.Short Interest Ratio / Days to CoveruniQure has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in uniQure has recently increased by 8.80%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YielduniQure does not currently pay a dividend.Dividend GrowthuniQure does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted17.99% of the float of uniQure has been sold short.Short Interest Ratio / Days to CoveruniQure has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in uniQure has recently increased by 8.80%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.67 News SentimentuniQure has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for uniQure this week, compared to 0 articles on an average week.Search Interest9 people have searched for QURE on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, uniQure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $322,426.00 in company stock.Percentage Held by InsidersOnly 4.79% of the stock of uniQure is held by insiders.Percentage Held by Institutions78.83% of the stock of uniQure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about uniQure's insider trading history. Receive QURE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QURE Stock News HeadlinesuniQure N.V. (NASDAQ:QURE) Receives $37.45 Consensus Target Price from AnalystsAugust 25 at 2:47 AM | americanbankingnews.comuniQure N.V. (QURE) Q2 2025 Earnings Call TranscriptJuly 29, 2025 | seekingalpha.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.August 27 at 2:00 AM | Brownstone Research (Ad)uniQure Narrows Loss in Fiscal Q2July 29, 2025 | fool.comuniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company ProgressJuly 29, 2025 | globenewswire.comuniQure to Announce Second Quarter 2025 Financial ResultsJuly 22, 2025 | globenewswire.comuniQure: Price And Value Have Caught UpJune 17, 2025 | seekingalpha.comuniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy OfficerJune 11, 2025 | globenewswire.comSee More Headlines QURE Stock Analysis - Frequently Asked Questions How have QURE shares performed this year? uniQure's stock was trading at $17.66 at the start of the year. Since then, QURE shares have decreased by 10.8% and is now trading at $15.75. How were uniQure's earnings last quarter? uniQure N.V. (NASDAQ:QURE) issued its quarterly earnings results on Tuesday, July, 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.20. The biotechnology company had revenue of $5.26 million for the quarter, compared to analysts' expectations of $5 million. uniQure had a negative trailing twelve-month return on equity of 1,010.74% and a negative net margin of 1,387.98%. Read the conference call transcript. Who are uniQure's major shareholders? Top institutional shareholders of uniQure include Vestal Point Capital LP (6.74%), Aberdeen Group plc (5.02%), Jefferies Financial Group Inc. (3.82%) and Nantahala Capital Management LLC (3.74%). Insiders that own company stock include Matthew C Kapusta, Christian Klemt, Ricardo Dolmetsch, Walid Abi-Saab, Jeannette Potts, Alexander Edward Kuta III, Pierre Caloz, Robert Gut, Madhavan Balachandran, Jeremy P Springhorn, David D Meek, Leonard E Post, Rachelle Suzanne Jacques, Jack Kaye and Paula Soteropoulos. View institutional ownership trends. How do I buy shares of uniQure? Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of uniQure own? Based on aggregate information from My MarketBeat watchlists, some other companies that uniQure investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings7/29/2025Today8/27/2025Next Earnings (Estimated)11/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:QURE CIK1590560 Webwww.uniqure.com Phone(120) 240-6000Fax31-20-566-9272Employees500Year FoundedN/APrice Target and Rating Average Price Target for uniQure$37.45 High Price Target$70.00 Low Price Target$20.00 Potential Upside/Downside+137.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($3.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$239.56 million Net Margins-1,387.98% Pretax Margin-1,375.80% Return on Equity-1,010.74% Return on Assets-33.27% Debt Debt-to-Equity Ratio1.53 Current Ratio9.98 Quick Ratio9.98 Sales & Book Value Annual Sales$27.12 million Price / Sales31.87 Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / Book-225.00Miscellaneous Outstanding Shares54,870,000Free Float52,239,000Market Cap$864.20 million OptionableOptionable Beta0.11 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:QURE) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding uniQure N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share uniQure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.